Freddy Keys
Family · Howell, MINPI 1134508120
Payments from drug & device makers
Across 141 payments — averaging $28.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- AbbVie$763
- Amgen$296
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$264
- Antares Pharma, Inc.$203
- Novo Nordisk$164
- plus $847 from 14 others
What the payments were for
- Travel & lodging$84621%
- Food & beverage$3,12679%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $1,434 |
| AbbVie | 39 | $763 |
| Amgen(2 entities) | 25 | $296 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $264 |
| Antares Pharma, Inc. | 8 | $203 |
| Novo Nordisk | 8 | $164 |
| Exact Sciences | 6 | $148 |
| Pfizer | 4 | $134 |
| Novartis | 5 | $113 |
| GSK | 5 | $108 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| UCB, Inc. | 2 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| AstraZeneca | 2 | $34 |
| Lundbeck LLC | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$3,971 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 64 | $91,848 |
| EliquisApixaban | 25 | $33,473 |
| OzempicSemaglutide | 15 | $19,847 |
| JardianceEmpagliflozin | 14 | $16,397 |
| JanuviaSitagliptin Phosphate | 14 | $16,276 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,185 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $1,048 |
| Rosuvastatin Calcium | 45 | $975 |
| Duloxetine Hcl | 27 | $944 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $876 |
| Atorvastatin Calcium | 62 | $738 |
| Doxycycline Hyclate | 142 | $736 |
| Trazodone Hcl | 15 | $650 |
| Levothyroxine Sodium | 49 | $586 |
| Cephalexin | 43 | $584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $134 | $33,47325 claims |
| Novo NordiskOzempic | $164 | $19,84715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.
Other family in Howell
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.